Feedback Sought on Pharmac Proposal to fund modified-release melatonin for insomnia in children and adolescents with neurodevelopmental disorders

Feedback Sought on Pharmac Proposal to fund modified-release melatonin for insomnia in children and adolescents with neurodevelopmental disorders

Some children with epilepsy may have multiple conditions, including neurodevelopmental disorders, if you have an interest in the proposal below Pharmac welcome your feedback – check out the full information on their website here.

Details of how to provide feedback below:

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on Friday, 26 May 2017 to:

Geraldine MacGibbon
Senior Therapeutic Group Manager/Team Leader
PHARMAC

Email: consult@pharmac.govt.nz

Fax:     04 460 4995
Post:   PO Box 10 254, Wellington 6143